← Back to All Filings

Exelixis EVP Sells $3.05M in EXEL Stock Across Multiple Transactions

Low SignificanceNovember 24, 2025 at 8:02:20 PM EST

EXELIXIS, INC.

$EXEL4CIK: 0000939767

Subscribe to track EXEL

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Exelixis EVP Sells $3.05M in EXEL Stock

Company: EXELIXIS, INC. (EXEL) Form: 4 | Filed: 2025-11-24 Significance: Low

Insider: Haley Patrick J. Title: EVP, Commercial | Relationship: Officer

Transaction: • Type: Sell • Shares: 72,230 • Avg. Price: $42.18 • Value: $3,047,191 • Owned After: 374,029 shares

Key Insight: An executive sold approximately $3.05 million worth of stock. While a large absolute number, the transaction represents a very small fraction (0.027%) of the company's $11.17 billion market capitalization, indicating low market significance.

Market Context: The sales were conducted across direct, spousal, and 401(k) accounts over two days. The sale constituted about 16.6% of the insider's previously reported holdings.

View Full Filing

Comprehensive Analysis

SEC Filing Analysis: EXELIXIS, INC. (EXEL)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: Exelixis's EVP of Commercial, Patrick J. Haley, sold a total of 72,230 shares for approximately $3.05 million.
  • Market Impact: The transaction is considered routine and unlikely to have a material impact on the stock, given its small size relative to the company's market capitalization.

Company Information

FieldValue
CompanyEXELIXIS, INC.
Ticker SymbolEXEL
CIK0000939767
IndustryBIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

FieldValue
NameHaley Patrick J.
CIK0001692954
Title/PositionEVP, Commercial
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-20
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved72,230 (aggregate)
Price Per Share~$42.18 (weighted average)
Total Value$3,047,191.17
Shares Owned After374,029
Ownership TypeMixed (Direct and Indirect sales)

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$3,047,191.17
% of Market Cap0.027%
Shares Transacted72,230
% of Shares Outstanding0.027%
Post-Transaction Ownership374,029 shares (0.14% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a large-cap company with an $11.17 billion market capitalization, a $3.05 million transaction is not financially material.
  • Ownership Concentration: The insider's post-transaction ownership of 374,029 shares (including unvested RSUs/PSUs) represents a minor stake of approximately 0.14% of total shares outstanding.
  • Transaction Significance: The sale represents approximately 16.6% of the insider's prior holdings. While a notable reduction for the individual, the overall market impact is negligible due to the low percentages relative to market cap and shares outstanding.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sale is too small (0.027% of market cap) to signal a significant change in insider sentiment or to influence market price. Such sales are common for executive compensation, diversification, or tax planning.

Volume & Sentiment

  • Expected Volume Impact: Minimal. The transaction size is unlikely to cause a noticeable impact on daily trading volume.
  • Sentiment Indicator: Neutral. This is a routine insider sale with low materiality.

Additional Context

Transaction Notes

  • Special Circumstances: The filing details four separate sale transactions occurring on November 20 and 21, 2025. The sales were from direct holdings, as well as indirect holdings via a spouse and a 401(k) plan. The reported prices are weighted averages.
Topics:#SECFiling#InsiderTrading#EXEL#Exelixis#Form4#InsiderSell#StockMarket#Biotech#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.